144 related articles for article (PubMed ID: 11001384)
1. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
2. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity.
Rasouli-Nia A; Liu D; Perdue S; Britten RA
Clin Cancer Res; 1998 May; 4(5):1111-6. PubMed ID: 9607567
[TBL] [Abstract][Full Text] [Related]
3. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.
Britten RA; Perdue S; Opoku J; Craighead P
Radiother Oncol; 1998 Sep; 48(3):329-34. PubMed ID: 9925253
[TBL] [Abstract][Full Text] [Related]
5. Taxane sensitivity of ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and cytotoxicity of 2alpha-amido docetaxel analogues.
Fang WS; Liu Y; Liu HY; Xu SF; Wang L; Fang QC
Bioorg Med Chem Lett; 2002 Jun; 12(11):1543-6. PubMed ID: 12031338
[TBL] [Abstract][Full Text] [Related]
8. Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Untch M; Untch A; Sevin BU; Angioli R; Perras JP; Koechli O; Averette HE
Anticancer Drugs; 1994 Feb; 5(1):24-30. PubMed ID: 7910494
[TBL] [Abstract][Full Text] [Related]
9. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
10. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Tanaka M; Obata T; Sasaki T
Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel in breast cancer and a rationale for combination therapy.
Hortobágyi G
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
17. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
Marth C; Zeimet AG; Widschwendter M; Ludescher C; Kaern J; Tropé C; Gastl G; Daxenbichler G; Dapunt O
Cancer Res; 1997 Sep; 57(17):3818-22. PubMed ID: 9288793
[TBL] [Abstract][Full Text] [Related]
19. Association of docetaxel/paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures.
Griffon-Etienne G; Merlin JL; Marchal C
Anticancer Drugs; 1996 Aug; 7(6):660-70. PubMed ID: 8913435
[TBL] [Abstract][Full Text] [Related]
20. Semi-synthesis of an O-glycosylated docetaxel analogue.
Nikolakakis A; Haidara K; Sauriol F; Mamer O; Zamir LO
Bioorg Med Chem; 2003 Apr; 11(7):1551-6. PubMed ID: 12628678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
